PE20171340A1 - Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales - Google Patents

Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales

Info

Publication number
PE20171340A1
PE20171340A1 PE2017001147A PE2017001147A PE20171340A1 PE 20171340 A1 PE20171340 A1 PE 20171340A1 PE 2017001147 A PE2017001147 A PE 2017001147A PE 2017001147 A PE2017001147 A PE 2017001147A PE 20171340 A1 PE20171340 A1 PE 20171340A1
Authority
PE
Peru
Prior art keywords
treatment
gastrointestinal diseases
pharmaceutical composition
bismuth
composition
Prior art date
Application number
PE2017001147A
Other languages
English (en)
Inventor
Young Ho Jo
Jun Woo Lee
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171340(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of PE20171340A1 publication Critical patent/PE20171340A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a una composicion que comprende: a) 50 mg a 300 mg de ranitidina; b) 240 mg a 1200 mg de sucralfato de bismuto; y c) 80 mg a 400 mg de subcitrato de bismuto. Dicha formulacion es estable y aumenta la biodisponibilidad biologica de los farmacos, siendo util en el tratamiento de de enfermedades gastrointestinales
PE2017001147A 2015-01-30 2016-01-28 Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales PE20171340A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (ko) 2015-01-30 2015-10-22 위장질환 치료용 의약 조성물

Publications (1)

Publication Number Publication Date
PE20171340A1 true PE20171340A1 (es) 2017-09-13

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001147A PE20171340A1 (es) 2015-01-30 2016-01-28 Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales

Country Status (19)

Country Link
EP (1) EP3250199A4 (es)
JP (1) JP6419347B2 (es)
KR (2) KR101583452B1 (es)
CN (1) CN107205947B (es)
AR (1) AR105413A1 (es)
CL (1) CL2017001680A1 (es)
CO (1) CO2017006222A2 (es)
EA (1) EA032385B9 (es)
EC (1) ECSP17038599A (es)
GE (1) GEP20196941B (es)
MA (1) MA41432A (es)
MX (1) MX2017007567A (es)
MY (1) MY195824A (es)
PE (1) PE20171340A1 (es)
PH (1) PH12017550051A1 (es)
SA (1) SA517382016B1 (es)
TW (1) TWI635859B (es)
UA (1) UA116517C2 (es)
WO (1) WO2016122226A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (ko) 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
WO2019199134A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 약제학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874917T2 (de) * 1987-03-09 1993-03-04 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (ko) * 1992-01-22 1997-04-23 주식회사 대웅제약 위장질환 치료용 의약 조성물
BR9507533A (pt) * 1994-04-26 1997-09-02 Chugai Pharmaceutical Co Ltd Preparações de sucralfato granulado fundido e um processo para sua produção
JPH0879097A (ja) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd 携帯無線機
KR970006083A (ko) 1995-07-06 1997-02-19 한승준 자동차용 카울부의 와이어 고정장치 취부구조
AU8354498A (en) * 1997-08-25 1999-03-16 Procter & Gamble Company, The Combined preparations for treating upper gastrointestinal tract distress
AU4655199A (en) * 1999-06-21 2001-01-09 Dae Woong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
WO2010001930A1 (ja) * 2008-07-01 2010-01-07 ライオン株式会社 固形内服製剤
KR20110105223A (ko) * 2010-03-18 2011-09-26 일양약품주식회사 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) * 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Also Published As

Publication number Publication date
PH12017550051A1 (en) 2018-01-29
BR112017013857A2 (pt) 2018-02-27
EA201791458A1 (ru) 2017-11-30
CO2017006222A2 (es) 2017-09-20
KR101583452B1 (ko) 2016-01-11
MY195824A (en) 2023-02-22
CL2017001680A1 (es) 2018-01-12
KR101583452B9 (ko) 2022-05-02
EP3250199A2 (en) 2017-12-06
WO2016122226A3 (en) 2016-09-15
EP3250199A4 (en) 2018-08-08
MA41432A (fr) 2017-12-05
SA517382016B1 (ar) 2021-03-18
AR105413A1 (es) 2017-10-04
GEP20196941B (en) 2019-01-10
EA032385B1 (ru) 2019-05-31
UA116517C2 (uk) 2018-03-26
ECSP17038599A (es) 2017-09-29
MX2017007567A (es) 2017-10-19
JP2018503672A (ja) 2018-02-08
WO2016122226A2 (en) 2016-08-04
CN107205947A (zh) 2017-09-26
CN107205947B (zh) 2020-05-22
TW201639559A (zh) 2016-11-16
KR20160094268A (ko) 2016-08-09
EA032385B9 (ru) 2019-07-31
TWI635859B (zh) 2018-09-21
JP6419347B2 (ja) 2018-11-07

Similar Documents

Publication Publication Date Title
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
CU20170009A7 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
BR112017016503A2 (pt) conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
BR112016027435A2 (pt) formulação inovadora de meloxicam
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
PE20171340A1 (es) Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
CL2017000026A1 (es) Formas de dosificación farmacéutica